“The fastest-growing platform for doctors in history” continues to step on the gas, and OpenEvidence is reportedly on the verge of notching a $3B valuation after inking a deal to bring JAMA Network journals to its AI medical search engine.
The multi-year content agreement will make full-text articles from the American Medical Association’s JAMA, JAMA Network Open, and 11 specialty journals available directly within the OpenEvidence platform.
- OpenEvidence’s medical search engine helps clinicians make decisions at the point of care, turning natural language queries into structured answers with detailed citations.
- The model was purpose-built for healthcare using training data from strategic partners like the New England Journal of Medicine, which joined the platform through a similar deal earlier this year.
The Disney+ content strategy has arrived in healthcare. OpenEvidence compares its approach to streaming services that drive subscriptions through exclusive movies.
- If a physician wants information from top journals to support decision making, they’ll either have to get it straight from the source or use OpenEvidence, just like how anyone who wants to stream Moana needs to go to Disney+.
- The kicker is that OpenEvidence is available at no cost to verified physicians, and advertising generates all of the revenue.
The blueprint is working like a charm. OpenEvidence has over 350k doctors using its platform plus another 50k joining each month, and it’s apparently close to raising $100M at a $3B valuation just a few months after closing its $75M Series A.
- It’s rare to find hockey stick growth in digital health, and OpenEvidence is a good reminder that many areas of healthcare change slowly… then all at once.
- It also isn’t too surprising to hear that VC’s like Google Ventures and Kleiner Perkins are lining up to fund a company with a similar ad-supported business model to Doximity – one of the only successful healthcare IPOs since the start of the pandemic.
The Takeaway
Content is king, and OpenEvidence is locking in partnerships to make sure its platform is wearing the crown. The results have been speaking for themselves, but healthcare’s genAI streaming wars are just getting started.
